Changes in plasma levels of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine after a single dose of vardenafil in patients with pulmonary hypertension

Henrohn, Dan; Sandqvist, Anna; Egeröd, Hanna; Hedeland, Mikael; Wernroth, Lisa; Bondesson, Ulf; Wikström, Gerhard

doi:10.1016/j.vph.2015.04.010

Cited by 12 publications

(10 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the reaction to hypoxia, the release of short‐lived mediators such as nitric oxide (NO) illustrates an essential mechanism in the control of vascular resistance and vascular cell proliferation . Nitric oxide is recognized as a potent pulmonary artery vasodilator and altered NO production was involved in the development of PH . NO is produced thanks to the conversion of l ‐arginine into l ‐citrulline by nitric oxide synthase (NOS).…”

Section: Introductionmentioning

confidence: 99%

“…DDAH‐1 is commonly located in tissues expressing neuronal NOS, whereas DDAH‐2 is observed predominated in tissues containing the endothelial isoform of NOS . Elevated ADMA levels were reported in patients with several diverse categories and subcategories of PH; idiopathic pulmonary arterial hypertension (IPAH), PAH related to congenital heart disease, chronic thromboembolic PH (CTEPH), PAH related to systemic sclerosis (SSc), and PAH related to chronic hemolytic anemia …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive pulmonary disease?

Telo

Kırkıl

Kuluöztürk

et al. 2017

Clinical Respiratory J

View full text Add to dashboard Cite

The mean age of patients was 69.21 ± 10.62, and 15 of these patients were females. There was no significant difference between the two COPD groups in terms of age and sex (P > .05). There was no difference in PaO , SaO , FEV and FEV /FVC values between the two COPD groups (P > .05). Serum ADMA levels were similar in the control and the COPD group (0.42 ± 0.13 vs 0.43 ± 0.15), but it was significantly higher in the COPD-PH group compared to the control and the COPD group (0.49 ± 0.14). A negative correlation was determined between serum ADMA levels and SaO levels (r = -.247, P = .028). A significant positive correlation observed between ADMA and systolic pulmonary artery pressure values (r = .627, P < .001) CONCLUSIONS: In conclusion, high levels of serum ADMA levels may be able to determine the presence of PH.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive pulmonary disease?

Telo

Kırkıl

Kuluöztürk

et al. 2017

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

“…We recently reported that plasma ADMA levels significantly decreased after a single oral dose of the PDE5-inhibitor vardenafil in patients with PH [ 23 ]. Furthermore, plasma l -arginine concentrations and the l -arginine/ADMA ratio increased over time and were correlated with changes in mean pulmonary artery pressure (mPAP), cardiac output (CO), and cardiac index (CI).…”

Section: Introductionmentioning

confidence: 99%

Plasma l-arginine levels distinguish pulmonary arterial hypertension from left ventricular systolic dysfunction

et al. 2017

Self Cite

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is a life-threatening condition, characterized by an imbalance of vasoactive substances and remodeling of pulmonary vasculature. Nitric oxide, formed from l-arginine, is essential for homeostasis and smooth muscle cell relaxation in PAH. Our aim was to compare plasma concentrations of l-arginine, asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA) in PAH compared to left ventricular systolic dysfunction (LVSD) and healthy subjects. This was an observational, multicenter study comparing 21 patients with PAH to 14 patients with LVSD and 27 healthy subjects. Physical examinations were obtained and blood samples were collected. Plasma levels of ADMA, SDMA, l-arginine, l-ornithine, and l-citrulline were analyzed using liquid chromatography–tandem mass spectrometry (LC–MS/MS). Plasma levels of ADMA and SDMA were higher, whereas l-arginine and l-arginine/ADMA ratio were lower in PAH patients compared to healthy subjects (p < 0.001). Patients with PAH also had lower levels of l-arginine than patients with LVSD (p < 0.05). l-Arginine correlated to 6 min walking distance (6MWD) (r s = 0.58, p = 0.006) and l-arginine/ADMA correlated to WHO functional class (r s = −0.46, p = 0.043) in PAH. In conclusion, l-arginine levels were significantly lower in treatment naïve PAH patients compared to patients with LVSD. Furthermore, l-arginine correlated with 6MWD in PAH. l-arginine may provide useful information in differentiating PAH from LVSD.

show abstract

“…18 In a human cohort of PAH patients, ADMA levels were reduced after oral administration of a phosphodiesterase-5 inhibitor. 19 …”

mentioning

confidence: 99%

Combined oral administration of L‐arginine and tetrahydrobiopterin in a rat model of pulmonary arterial hypertension

et al. 2017

View full text Add to dashboard Cite

Alterations in the nitric oxide (NO) pathway play a major role in pulmonary arterial hypertension (PAH). L-arginine (LA) and tetrahydrobiopterin (BH4) are main substrates in the production of NO, which mediates pulmonary vasodilation. Administration of either LA or BH4 decrease pulmonary artery pressure (PAP). A combined administration of both may have synergistic effects in the therapy of PAH. In a telemetrically monitored model of unilateral pneumonectomy and monocrotaline-induced PAH, male Sprague-Dawley rats received either LA (300 mg/kg; n = 15), BH4 (20 mg/kg; n = 15), the combination of LA and BH4 (300 mg/kg, 20 mg/kg; n = 15), or vehicle (control group; n = 10) from day 28 after monocrotaline induction. Therapy was orally administered once daily over consecutive 14 days. LA, BH4, or both equally lowered PAP, increased pulmonary vascular elasticity, restored spontaneous locomotoric activity, prevented body weight loss and palliated small vessel disease of severely pulmonary hypertensive rats. BH4 substitution lowered asymmetric dimethylarginine levels sustainably at 60 min after administration and downregulated endothelial NO synthase mRNA expression. No significant survival, macro- and histomorphologic or hemodynamic differences were found between therapy groups at the end of the study period. Administration of LA and BH4 both mediated a decrease of mean PAP, attenuated right ventricular hypertrophy and small vessel disease in monocrotaline-induced pulmonary hypertensive rats, though a combined administration of both substances did not reveal any synergistic therapy effects in our animal model.

show abstract

Changes in plasma levels of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine after a single dose of vardenafil in patients with pulmonary hypertension

Cited by 12 publications

References 47 publications

Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive pulmonary disease?

Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive pulmonary disease?

Plasma l-arginine levels distinguish pulmonary arterial hypertension from left ventricular systolic dysfunction

Combined oral administration of L‐arginine and tetrahydrobiopterin in a rat model of pulmonary arterial hypertension

Contact Info

Product

Resources

About